Jazz Pharmaceuticals plc (JAZZ) 追踪市盈率为负值 -33.3, 表示公司目前在过去十二个月 (TTM) 基础上处于亏损状态。 前瞻市盈率 8.3 基于分析师预估，预计将恢复盈利。 追踪盈利收益率为 -3.00%, 前瞻盈利收益率 12.08%. PEG 1.10.
本页证实的标准:
SharesGrow 综合评分： 57/100 其中 3/7 项标准通过。
| Year | P/E (TTM) | PEG 比率 | P/B 比率 | P/S 比率 | 股息收益率 |
|---|---|---|---|---|---|
| 2016 | 16.6 | 0.76 | 3.51 | 4.43 | - |
| 2017 | 16.6 | 0.69 | 2.98 | 4.99 | - |
| 2018 | 16.6 | -1.99 | 2.70 | 3.93 | - |
| 2019 | 16.2 | 0.68 | 2.72 | 3.92 | - |
| 2020 | 38.5 | -0.72 | 2.51 | 3.89 | - |
| 2021 | -23.1 | 0.10 | 1.92 | 2.46 | - |
| 2022 | -44.5 | 1.27 | 3.23 | 2.72 | - |
| 2023 | 18.8 | -0.07 | 2.08 | 2.03 | - |
| 2024 | 13.6 | 0.35 | 1.86 | 1.87 | - |
| 2025 | -29.1 | 0.18 | 2.40 | 2.43 | - |
| Year | EPS（稀释） | 营收 | 净利润 | 净利润率 |
|---|---|---|---|---|
| 2016 | $6.41 | $1.49B | $396.83M | 26.7% |
| 2017 | $7.96 | $1.62B | $487.85M | 30.1% |
| 2018 | $7.30 | $1.89B | $447.1M | 23.6% |
| 2019 | $9.09 | $2.16B | $523.37M | 24.2% |
| 2020 | $4.22 | $2.36B | $238.62M | 10.1% |
| 2021 | $-5.51 | $3.09B | $-328.95M | -10.6% |
| 2022 | $-3.42 | $3.66B | $-214.14M | -5.9% |
| 2023 | $6.10 | $3.83B | $414.83M | 10.8% |
| 2024 | $8.65 | $4.07B | $560.12M | 13.8% |
| 2025 | $-5.84 | $4.27B | $-356.15M | -8.3% |
| Year | EPS（平均） | EPS 范围 | 营收（平均） | 营收范围 | 分析师人数 |
|---|---|---|---|---|---|
| 2026 | $23.94 | $22.15 – $26.00 | $4.44B | $4.39B – $4.49B | 10 |
| 2027 | $25.01 | $22.94 – $29.07 | $4.79B | $4.62B – $4.98B | 10 |
| 2028 | $26.70 | $20.10 – $32.75 | $5.18B | $5.16B – $5.2B | 4 |
| 2029 | $30.88 | $29.67 – $32.25 | $5.76B | $5.59B – $5.96B | 2 |
| 2030 | $31.98 | $30.74 – $33.40 | $6.02B | $5.84B – $6.22B | 2 |
